Overview
Celgene Corp : CELG
Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
News
-
01 Mar 2021
Greencoat Renewables recaps on a big year of growth
Greencoat Renewables (GRP) reported final results for the year to 31 December 2020, with key highlights from the year including the following: 2020 Generation increased by 22% to 1,404GWh, 3 per cent below budget. (2019: 1,154GWh) 2020 Net cash generation increased by 36% to €66.4 million (2019: €48.7million) Dividend cover for 2020 of 1.7x Increased the portfolio […]
-
16 Aug 2018
IBT adds to Celgene, reduces Neurocrine in July rejig
IBT adds to Celgene, reduces Neurocrine in July rejig International Biotechnology Trust (IBT) appears to have boosted its shareholding in Celgene – which has risen by one place and ~ two NAV percentage points to become its top investee company, as part of a rejig of its largest investments in July. According to the trust’s latest […]
-
02 Aug 2018
HBM sees best share price performance in YTD period
HBM sees best share price performance in YTD period London-listed HBM Healthcare (HBMN) recorded the best share price price performance so far this year of the 14 biotech specialist investment trusts monitored by Marten & Co, with a 25% rise in the seven months to end July. HBM’s share price outstripped growth in NAV, which […]
-
10 Jul 2018
Celgene claims win for luspatercept in Believe trial
Celgene claims win for luspatercept in Believe trial Specialist trust favourite Celgene (Nasdaq: CELG) has reported positive result in a Phase III trial with the drug candidate luspatercept for treatment of anaemia associated with beta-thalassemia. This follows the company’s success in the Medalist Phase III trial win with the same drug in anaemia associated with myelodysplastic syndrome (MDS). The unambiguous […]
-
29 Jun 2018
Trust favourite Celgene claims win in Medalist trial
Trust favourite Celgene claims win in Medalist trial US biotech and specialist trust favourite Celgene (Nasdaq: CELG) has reported a positive result in a closely-watched Phase III trial that was being seen as a key step necessary in its rehabilitation with investors. The trial was of the drug candidate luspatercept for treatment of anaemia associated with a type […]
-
03 Jan 2018
Biotech bellwether Celgene to report key update next week
Biotech bellwether Celgene to report key update next week Investors in the main sector specialist investment trusts should watch for an important update from Celgene early next week at the annual JP Morgan Healthcare Conference, the largest and most important investor event in the sector. The US biotech group is expected to “pre-announce” Q4 sales […]
